FDA – Page 5 – Policy & Medicine

Magellan Executives Charged with Conspiracy, Wire Fraud, and FDA Violations

OPDP: No More Untitled Letters?

FDA Issues Draft Guidance on Dosage and Administration Labeling Section

Policy and Medicine March 2022 Issue Features FDA Exclusivity, Baby Powder, and FCA Case Dismissal

Could Simplified Clinical Trials Lead to More Diversity?

2022 FDA New Drug Approvals Lowest Since 2016

Two Biotech Executives Charged in Securities Fraud Scheme

FDA Receives Increased Budget for FY 2023

Congressional Report Released on FDA’s Improper Actions in Aduhelm Approval Process

Omnibus Bill Includes Changes to Pharmaceutical and Device Investigational Pre-Market Communications